Abstract: Disclosed herein are 5,?-dimethylthieno[2,3-d]pyrimidine derivatives useful as antiviral agents. More particularly, disclosed are 5,?-dimethylthieno[2,3-djpyrimidine derivatives represented by Formula 1, having an excellent inhibitory effect on the proliferation of hepatitis C virus (HCV), pharmaceutically acceptable salts thereof, a preparation method thereof, and a pharmaceutical composition for the prevention and treatment of hepatitis C virus (HCV), containing, as active ingredients, these compounds. The 5,6-dimethylthieno[2,3-d]pyrimidine derivatives represented by Formula 1 have an excellent effect of inhibiting the proliferation of hepatitis C virus and also have low toxicity. Thus, these compounds are available as agents for the prevention and treatment of hepatitis C.
Type:
Grant
Filed:
September 23, 2005
Date of Patent:
October 19, 2010
Assignee:
Equispharm Co., Ltd
Inventors:
Cheol Kyu Han, Jeonghyeok Yoon, Nam-Doo Kim, Jin-ah Kim
Abstract: Disclosed herein are 5,?-dimethylthieno[2,3-d]pyrimidine derivatives useful as antiviral agents. More particularly, disclosed are 5,?-dimethylthieno[2,3-djpyrimidine derivatives represented by Formula 1, having an excellent inhibitory effect on the proliferation of hepatitis C virus (HCV), pharmaceutically acceptable salts thereof, a preparation method thereof, and a pharmaceutical composition for the prevention and treatment of hepatitis C virus (HCV), containing, as active ingredients, these compounds. The 5,6-dimethylthieno[2,3-d]pyrimidine derivatives represented by Formula 1 have an excellent effect of inhibiting the proliferation of hepatitis C virus and also have low toxicity. Thus, these compounds are available as agents for the prevention and treatment of hepatitis C.
Type:
Application
Filed:
September 23, 2005
Publication date:
September 25, 2008
Applicant:
EQUISPHARM CO., LTD
Inventors:
Cheol Kyu Han, Jeonghyeok Yoon, Nam-Doo Kim, Jin-ah Kim
Abstract: The disclosure relates to a fumagillol compound which can be usefully used not only as an angiogenesis inhibiting agent showing a superior angeogenesis inhibitory effect with less toxicity, but also as a cancer metastasis inhibitor and a therapeutic agent against cancer and other various inflammatory diseases such as rheumatic disease, psoriasis, etc., and diabetic retinopathy related to angeogeneois, and also a method for preparing the same.
Type:
Grant
Filed:
June 11, 2002
Date of Patent:
August 8, 2006
Assignee:
Equispharm Co., Ltd.
Inventors:
Cheol-Kyu Han, Jeong-Hyeok Yoon, Seung-Moak Kim, Nam-Doo Kim, Byung-Ha Chang, Jee-Young Lee, Tae-Bo Sim